Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Clinical trial NCT00820222 · COMPLETED

Trial details

NCT number: NCT00820222
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Metastases, Brain

Start date: 2009-04-14
Primary completion: 2012-06-11
Enrollment: 540

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.